SOUTH SAN FRANCISCO, Calif. and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on ...
A tissue section from a mouse model of lung metastasis showing cancer cells (green) that have attracted and activated fibroblasts (red) to support the growth of a metastatic tumor. Image: Massagué Lab ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Digital twin technology can reliably simulate standard-of-care treatment outcomes using historical clinical trial data, ...
Hosted on MSN
Experimental drug findings pave way for clinical trial to target cancer's elusive growth switch
Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key ...
CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 / Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a ...
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers Based ...
As I mentioned in the previous blog, we are pleased to announce the addition of Dr. Ashley Cannon, a genetic counselor and clinical researcher, to our team of specialists in the UAB NF Clinic. With a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results